VRPX (virpaxpharma.com) Net Profit

VRPX (Virpax Pharmaceuticals, Inc.) - company brandmark

The absence of stable cash flows makes the asset dependent on clinical trial outcomes. Virpax Pharmaceuticals (VRPX) seeks expansion in the non-opioid pain management segment through innovative nasal delivery methods for CNS drugs. The company's profit confirms the market consensus, demonstrating a metric value of -0.01. However, high testing costs and regulatory barriers create significant financial risks for the issuer.

VRPX (Virpax Pharmaceuticals, Inc.) Company Net Income history from 07/04/2022 to 04/13/2025

Comprehensive metric breakdowns and analytics for virpaxpharma.com (VRPX)

- price and consensus price forecast:
Stock Quotes Virpax Pharmaceuticals, Inc.|VRPX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Virpax Pharmaceuticals, Inc.|VRPX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Virpax Pharmaceuticals|VRPX - Company Book Value|Market Capitalization to Net Assets virpaxpharma.com|VRPX - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Coefficient Virpax Pharmaceuticals|VRPX - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Virpax Pharmaceuticals, Inc.|VRPX - Company Aggregate Debts|Debt to Book Value Virpax Pharmaceuticals, Inc.|VRPX - Company Long-Term Debts|Company Short-Term Loans and Borrowings Virpax Pharmaceuticals|Immediate Liquidity virpaxpharma.com
- net income and valuation multiples indicators:
VRPX - Net Income
Fundamental valuation:VRPX, Virpax
Mass-produced product of Virpax Pharmaceuticals

The stability of Virpax Pharmaceuticals (VRPX) is driven by its success in developing non-opioid analgesics and the implementation of the Envelta system. This metric measures daily operating cash flow, excluding accounting lags, to assess the business's real-time resilience to macroeconomic shocks. Continuous monitoring of the balance between expansion and drawdown risks through the company's earnings history allows investors to immediately capture fundamental shifts in technology commercialization.

Direct competitors

Net Income Alkermes Corp|AVDL (Avadel Pharmaceuticals) - Net Profit|Net Profit atai.life|Net Income GHRS (GH Research)|MNMD (Mind Medicine (MindMed) Inc.) - Final Profit|Company Net Income Compass Pathways CMPS|LBRX (LB Corp) - Profit After Tax|DRUG - Company Net Income|Net Financial Result vandapharma.com VNDA|CYBN (cybin.com) - Net Income|Company Net Income Alto Neuroscience Inc (ANRO)|NRXP (NRx Pharma) - Net Profit|Net Income Cingulate Corp (CING)|Net Profit SILO|CPHI (chinapharmaholdings.com) - Final Profit|Company Net Income Clearmind Medicine Inc. CMND|Psyence Biomedical Ltd (PBM) - Company Net Income|SPRC: Net Income|SEEL: Company Net Income|KRTX: Net Profit